AVI BioPharma, Inc. To Present At 7th Annual Biodefense Vaccines & Therapeutics Conference In Washington, D.C.

Main Category: Immune System / Vaccines
Also Included In: Pharma Industry / Biotech Industry
Article Date: 12 Jun 2009 - 2:00 PDT

email to a friend   printer friendly   view / write opinions

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming 7th Annual Biodefense Vaccines & Therapeutics conference taking place in Washington, D.C.

Dr. Iversen will present on Monday, June 15, as part of a pre-conference symposium on "Developments in Biodefense Technology Platform." He will be a featured speaker in a session titled "Building Technology Platforms to Array Against Multiple Threats," where he will discuss the utility of AVI's RNA-based drugs against biological threats, including Ebola and Marburg viruses. AVI has begun to evaluate the rapid mobilization of RNA-based drugs against positive and negative strand RNA viruses. This analysis includes target optimization, avoidance of drug resistance and the relative advantages of virus-specific and host immune response-specific therapeutics to both improve host protection and reduce disease.

Information about the conference can be found here.

Source
AVI BioPharma